HONG KONG, March 24, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced today that it has received clearance from the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) to initiate Phase II clinical trials for AK146D1, a first-in-class Trop2 /Nectin4 bispecific antibody-drug conjugate (ADC), and AK138D1, an innovative HER3-targeting ADC. The studies will evaluate these two novel ADC candidates in combination with the Company'

BEIJING, March 24, 2026 /PRNewswire/ -- A research team led by Prof. Hesheng Liu, founder and Chief Scientific Officer of Galaxy Brain Scientific Inc., has published a study in Nature Neuroscience demonstrating that Deep Brain Stimulation (DBS) achieves therapeutic efficacy in Parkinson's disease (PD) by remodeling the SPARK circuit. () Continue Reading The findings build directly on the team's previous identification of a core cortico-subcortical PD circuit derived from the somato-cognitive act

SHANGHAI, March 24, 2026 /PRNewswire/ -- Hope Medicine Inc., a science-driven, clinical-stage innovative biopharmaceutical company, announced that the first patient has been dosed in the Phase III clinical trial of HMI-115, its first-in-class monoclonal antibody with global rights, for the treatment of endometriosis. The dosing took place at the leading study site in China, Peking Union Medical College Hospital. This Phase III trial is a multicenter, randomized, double-blind, placebo-controlled

-- Additional data from RSV re-vaccination trial demonstrates trend of approximately 60-80% higher RSV neutralizing antibodies (nAbs) for Clover's RSV vaccine compared head-to-head versus AREXVY (GSK) in older adults who previously received an initial dose of AREXVY -- -- Re-vaccination with Clover's RSV vaccine boosted RSV nAbs to approximately 120-135% of the peak levels observed after an initial dose of AREXVY (cross-trial comparison) -- -- Results further strengthen profile of potential best

Grounded in the world's largest fertility pricing dataset, the system is designed to catch billing abuse that traditional systems miss. DES MOINES, March 24, 2026 /PRNewswire/ -- Billions of employer dollars are flowing into global fertility and family-building care. Almost no one is watching where they go. The global surrogacy market alone is projected to reach $201.8 billion by 2034. Cross-border fertility care is accelerating as employees travel internationally for IVF, egg freezing, donor se

Trim Tactics, a medical aesthetics and wellness clinic in Lubbock, reports encouraging patient results following introduction of new hair restoration protocol. Combining RF microneedling with plant-derived exosome therapy allows the clinic to provide a treatment option that many patients find accessible while still delivering visible improvements.” — Valton Cooper LUBBOCK, TX, UNITED STATES, March 24, 2026 / EINPresswire.com / -- Trim Tactics , a medical aesthetics and wellness clinic in Lubbock

In the news release, Roche launches the cobas eplex respiratory pathogen panel 3, a fast and comprehensive test to help clinicians treat patients with respiratory infections, in CE markets, issued 24-Mar-2026 by Roche over PR Newswire, we are advised by the company that changes have been made. The complete, corrected release follows, with additional details at the end: Roche launches the cobas eplex respiratory pathogen panel 3, a fast and comprehensive test to help clinicians treat patients wit

REHOVOT, Israel, March 24, 2026 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetic medicine company developing innovative technologies and products based on its proprietary recombinant human collagen (rhCollagen) platform, today announced that on March 23, 2026, the Company received a written notice (the "Notice") from the Nasdaq Stock Market LLC indicating that the Company was not in compliance with Nasdaq Listing Rule 5550(a)(2), as the Company's closing bid

First tenant milestone validates Rowen's innovation community model and signals the start of a new life sciences hub in Gwinnett County GWINNETT COUNTY, Ga., March 24, 2026 /PRNewswire/ -- The State of Georgia, Gwinnett County and the Rowen Foundation today announced that global biopharmaceutical company UCB has selected Rowen as the site of its new U.S. biologics manufacturing campus. The planned project represents a direct investment of approximately $2 billion and is expected to create more t

WASHINGTON, March 24, 2026 /PRNewswire/ -- The National Association for Biomedical Research condemns the alleged unlawful, violent actions of animal rights extremists who on March 15th are alleged to have trespassed on and damaged the property of a Midwest research and breeding facility. NABR stands in solidarity with the greater research community in condemning such illegal activity committed by animal rights extremists. Continue Reading On March 15th approximately 50-60 animal rights extremist